Anthropic Cure Claims Meet Pharma Pushback

The article punctures Silicon Valley’s most aggressive AI-for-science timelines without dismissing the technology’s real utility. The bottleneck is not generating hypotheses—it is validating them through complex biology, experiments, safety testing, and clinical trials.

• –Vertex tested roughly 50 AI companies across 10,000 compounds without producing a working drug.
• –AI is already useful for target selection, molecule screening, patient matching, protein analysis, and experiment design.
• –Drugmakers say models still struggle with off-target effects and the biological complexity behind clinical failure.
• –Amodei’s own essay acknowledges physical-world latency, missing data, intrinsic complexity, and regulatory constraints. [Essay](https://darioamodei.com/essay/machines-of-loving-grace)
• –For developers, the durable opportunity is evidence-driven lab tooling—not demos that imply models can replace drug scientists. [AHCJ report](https://healthjournalism.org/blog/2026/10/biotech-experts-debunk-the-hype-around-ai-disease-cures)